【华创医药】时代天使（06699.HK）深度研究报告：国产隐形正畸龙头——本土崛起，出海破局

Core Viewpoint - The company is a leading provider of invisible orthodontic technology and products in China, having surpassed competitors in domestic market share since 2021, with robust performance despite industry pressures. The rapid growth of overseas business has significantly contributed to overall revenue, with overseas cases expected to reach approximately 140,700 in 2024, a year-on-year increase of 326% [3]. Group 1: Domestic Business Growth - The domestic invisible orthodontics market has substantial growth potential, with penetration rates nearing 16% in 2024, compared to 32% in the U.S. in 2020, indicating room for improvement, particularly in the youth/children and grassroots markets [4]. - Market concentration is increasing due to competitive pressures and policy changes, benefiting leading companies like this one as smaller players exit the market [4]. Group 2: International Expansion Potential - The global invisible orthodontics market is significantly larger than the domestic market, with case numbers being eight times higher. The company has opportunities to penetrate markets in the U.S., Europe, Asia-Pacific, and Latin America, where there is considerable room for growth [5]. - The company has established a comprehensive product system and is enhancing its competitive edge through continuous R&D and digital upgrades, leveraging a vast clinical database for complex case handling [5]. - The company’s global market share has increased from 4.5% in 2022 to 10.1% in 2025, with expectations to reach over 20% in the future as it enters a new phase of international expansion [6]. Group 3: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at $337 million, $412 million, and $495 million, with net profits of $27 million, $22 million, and $41 million respectively. The company is currently in a growth phase for its overseas business and is valued using a PS method, with a target market value of HKD 15.45 billion and a target share price of HKD 90.5 [6].